Substance / Medication

Teduglutide

Overview

Active Ingredient
teduglutide
RxNorm CUI
1364468

Indications

® . GATTEXis indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support

Labeler: Takeda Pharmaceuticals America, Inc.Updated: 2025-09-05T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis.
Bioletto Fabio, D'Eusebio Chiara, Merlo Fabio Dario et al. · Nutrients · 2022
PMID: 35215445Meta-AnalysisFull text (PMC)
Use of Teduglutide in Children With Intestinal Failure: A Systematic Review.
Gigola Francesca, Cianci Maria Chiara, Cirocchi Roberto et al. · Front Nutr · 2022
PMID: 35774551Meta-AnalysisFull text (PMC)
Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.
Naberhuis Jane K, Tappenden Kelly A · JPEN J Parenter Enteral Nutr · 2016
PMID: 25883117Meta-Analysis
Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease.
Marier Jean-Francois, Mouksassi Mohamad-Samer, Gosselin Nathalie H et al. · J Clin Pharmacol · 2010
PMID: 19773525Meta-Analysis
Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.
Micic Dejan, Robinson Ian, Kidd Tanya et al. · Nutr Clin Pract · 2024
PMID: 38491966RCT
Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.
Chiba Masahiro, Masumoto Kouji, Kaji Tatsuru et al. · J Pediatr Gastroenterol Nutr · 2023
PMID: 37364133RCTFull text (PMC)
Teduglutide for the treatment of low-output enterocutaneous fistula - A pilot randomized controlled study.
Yeh D Dante, Vasileiou Georgia, Abdul Jawad Khaled et al. · Clin Nutr ESPEN · 2022
PMID: 35871951RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Teduglutide (substance)
SNOMED CT
710807004
UMLS CUI
C1530889
RxNorm CUI
1364468
Labeler
Takeda Pharmaceuticals America, Inc.

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.